Monitor for imminent takedown of shares under this shelf; any offering will be highly dilutive given current market cap. Downward pressure on share price is likely upon announcement of any issuance.
INM drugs
INM drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 31 $0.6450entry
- T+1 · 8mo ago +3.88%α +3.13% · $0.6700
- T+5 · 7mo ago +0.31%α −3.63% · $0.6470
- T+20 · 7mo ago +8.68%α −0.74% · $0.7010
- T+60 · 5mo ago +138.76%α +126.38% · $1.54
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
InMed Pharmaceuticals' S-3 shelf registration has become effective, allowing the company to raise up to $50 million through future offerings of common shares, preferred shares, warrants, or other securities. Given the company's $2 million market cap and existing going concern doubts, this creates a significant dilution overhang.
Key Facts
- S-3 shelf registration became effective on March 30, 2026
- Company may raise up to $50 million in aggregate value over time
- Offering can include common stock, preferred stock, warrants, subscription rights, or units
- Market cap is only $2 million, implying potential for extreme dilution
- Company faces substantial doubt about going concern due to operating losses and adverse U.S. legislation impacting BayMedica
Financial Impact
Up to $50 million in potential dilution against a $2 million market cap
Risk Factors
- Extreme shareholder dilution due to large shelf size relative to market cap
- Equity issuances could further depress share price in a low-liquidity environment
- Ongoing going concern risks exacerbated by reliance on capital markets for survival
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-000999 |
| Document: 9999999995-26-000999-index.html | 9999999995-26-000999 |
| Document: 9999999995-26-000999.txt | 9999999995-26-000999 |
Track record
22 reports on INM
6 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +24.51% at T+1 after the Nov 3, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $16.00 Now $19.87 +24.19% settles Dec 8
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
- Nov 3, 202613d ago 8-K Bearish 6/10 Entry $1.75 Now $19.87 −1035.43% settles Dec 3
- Nov 2, 202614d ago 425 Neutral 3/10 Entry $1.68 Now $19.87 +1082.74% settles Dec 2
- Oct 26, 202621d ago 425 Neutral 3/10 Entry $1.59 Now $19.87 +1149.69% settles Nov 24
- Oct 7, 20265w ago SC 13G/A Bullish 5/10 Entry $1.33 to $1.32 Now $19.87 +1393.99% ▼ −0.68% +4.61% vs SPY
- Oct 2, 20266w ago EFFECT Neutral 3/10 Entry $1.33 to $1.60 Now $19.87 +1393.99% ▲ +20.30% +22.11% vs SPY
- Sep 18, 20268w ago 8-K Bearish 6/10 Entry $1.38 to $1.37 Now $19.87 −1339.86% ▲ +1.06% +0.15% vs SPY
- Sep 9, 20269w ago 425 Neutral 6/10 Entry $1.31 to $1.33 Now $19.87 +1416.79% ▲ +1.53% −0.60% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers